NASDAQ: CUVL
Clinuvel Pharmaceuticals Ltd Earnings Dates, Reports, Calls

Clinuvel Pharmaceuticals earnings were $23.1M for the trailing 12 months ending Jun 30, 2025, with -2.1% growth year over year. The latest CUVL earnings report on Jun 30, 2025 announced Q2 2025 earnings of N/A, down N/A from last quarter. For the last reported fiscal year 2025 ending Jun 30, 2025, CUVL reported annual earnings of $23.1M, with -1% growth.

CUVL past earnings growth

How has CUVL's earnings growth performed historically?

Company
-2.13%
Industry
N/A
Market
83.39%
CUVL's earnings have grown slower... subscribe to Premium to read more.
Earnings Growth vs Market Performance

CUVL earnings history

Current Revenue
$61.1M
Current Earnings
$23.1M
Current Profit Margin
37.8%

CUVL Return on Equity

Current Company
15.8%
Current Industry
30.7%
Current Market
30.7%

CUVL Return on Assets

Current Company
14%
Current Industry
13.9%

Be the first to know when CUVL announces earnings.

CUVL Return on Capital Employed

Current Company
20.8%
Current Industry
22.2%

Clinuvel Pharmaceuticals Earnings Reports & History FAQ

What were Clinuvel Pharmaceuticals's earnings last quarter?

Clinuvel Pharmaceuticals (NASDAQ: CUVL) reported Q2 2025 earnings per share (EPS) of N/A, up N/A year over year. Total CUVL earnings for the quarter were N/A. In the same quarter last year, Clinuvel Pharmaceuticals's earnings per share (EPS) was N/A.

If you're new to stock investing, here's how to buy Clinuvel Pharmaceuticals stock.

Is Clinuvel Pharmaceuticals profitable or losing money?

As of the last Clinuvel Pharmaceuticals earnings report, Clinuvel Pharmaceuticals is currently profitable. Clinuvel Pharmaceuticals's net profit (also called net income) for the twelve months ending Jun 30, 2025 was $23.12 million, a 0.96% decrease year over year.

What was CUVL's earnings growth in the past year?

As of Clinuvel Pharmaceuticals's earnings date in Q3 2026, Clinuvel Pharmaceuticals's earnings has grown -2.13% year over year. CUVL earnings in the past year totalled $23.12 million.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.